Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy Chinese infants
CTR20262768Phase 3Active
- Sponsor
- Pfizer
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Prevnar 20 in invasive pneumococcal disease (IPD), sponsored by Pfizer. Started Jul 2026; status: active.
02
Drugs
Prevnar 20
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on CTR20262768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262768.